Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
Study Details
Study Description
Brief Summary
The stunning response rate of anti-CD19(cluster of differentiation antigen 19) auto-CAR(chimeric antigen receptor)-T cell therapy brings hope to patients with relapsed or refractory B-cell hematologic malignancies. However, based on open clinical trials, using patients' T cells might encounter the failure of apheresis available T cells, even if successful, the time needed for the manufacture could also cause the irreversible disease progress. Furthermore, the cost of auto-CAR-T cells is not affordable for most patients. So to provide an accessible and affordable anti-CD19 CAR-T cell therapy for patients with B-cell hematologic malignancies, we launch such a trial that using the edited T cells from healthy donors to manufacture universal CAR-T cells and adapt it in patients with CD19+ B-cell leukemia or lymphoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Early Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: anti-CD19 UCAR-T cells After preconditioning with chemotherapy ( Fludarabine, Cytoxan and/or Melphalan), the dosage of anti-CD19 UCAR-T cells between 1 and 5 ×10^7 cells/Kg will be evaluated |
Biological: anti-CD19 UCAR-T cells
Dose range:1 to 5 ×10^7 cells/Kg, Dose level one: 1×10^7 cells/Kg, Dose level two: 3×10^7 cells/Kg, Dose level three:5 ×10^7 cells/Kg
Drug: Fludarabine
30mg/m^2 per day for 6 days
Drug: Cytoxan
300mg/m^2 per day for 2 to 6 days determined by tumor burden at baseline
Drug: Melphalan
50 to 70 mg/m^2 in total for 1 or 2 days, whether to use determined by tumor burden at baseline
|
Outcome Measures
Primary Outcome Measures
- the anti-tumor efficiency of anti-CD19 UCAR-T cells [4 weeks after infusion]
ratio of bone marrow blast cells and/or the measurable lesion size and strandralized uptake value
Secondary Outcome Measures
- the long-term efficiency of anti-CD19 UCAR-T cells [3 and 6 months after infusion]
ratio of bone marrow blast cells and/or the measurable lesion size and strandralized uptake value
Eligibility Criteria
Criteria
Inclusion Criteria:
-
- Diagnosis of recurrent B-cell acute lymphoblastic leukemia (B-ALL), B-cell acute lymphoblastic lymphoma (B-LLy), or B-non-Hodgkin lymphoma (B-NHL)
-
CD19-positive tumor (≥20% CD19 positive blasts by flow cytometry or immunohistochemistry (tissue))
-
Hgb ≥ 7.0 (can be transfused)
-
Life expectancy greater than 12 weeks
-
Informed consent explained to, understood by and signed by the patient/guardian. The patient/guardian is given a copy of informed consent.
Exclusion Criteria:
-
Pregnant or lactating.
-
Tumor in a location where enlargement could cause airway obstruction (per investigator discretion).
-
Active infection with HIV or HTLV.
-
Clinically significant viral infection or uncontrolled viral reactivation of EBV(Epstein-Barr virus), CMV(cytomegalovirus), ADV(adenovirus), BK-virus, or HHV(human herpesvirus)-6.
-
Any of the following cardiac criteria: Atrial fibrillation/flutter; Myocardial infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT, per investigator discretion. Cardiac echocardiography with LVSF (left ventricular shortening fraction)<30% or LVEF(left ventricular ejection fraction)<50%; or clinically significant pericardial effusion. Cardiac dysfunction NYHA(New York Heart Association) III or IV (Confirmation of absence of these conditions on echocardiogram within 12 months of treatment).
-
CNS abnormalities: Presence of CNS(central nervous system)-3 disease defined as detectable cerebrospinal blast cells in a sample of CSF(cerebrospinal fluid) with ≥ 5 WBC( white blood cell)s per mm3 (unless negative by the Steinherz/Bleyer algorithm); Presence of any CNS disorder such as an uncontrolled seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Department of Hematology, Xinqiao Hospital | ChongQing | Chongqing | China | 400037 |
Sponsors and Collaborators
- Xinqiao Hospital of Chongqing
- Gracell Biotechnology Shanghai Co., Ltd.
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- The Second Affiliated Hospital of Chongqing Medical University
- The Affiliated Hospital Of Guizhou Medical University
- Central South University
- The First Affiliated Hospital of Kunming Medical College
- The General Hospital of Western Theater Command
- Second Affiliated Hospital of Xi'an Jiaotong University
- Nanfang Hospital of Southern Medical University
- Fujian Medical University Union Hospital
- The First Affiliated Hospital of Anhui Medical University
- Tang-Du Hospital
Investigators
- Principal Investigator: Xi Zhang, MD, Xinqiao Hospital of Chongqing
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- antiCD19-UCAR-T